Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

resTORbio

resTORbio
2017 FOUNDED
PUBLIC STATUS
21-30 EMPLOYEES
TORC STOCK SYMBOL
$7.44 SHARE PRICE (As of Thursday Closing)
Description

resTORbio Inc is a clinical-stage biopharmaceutical company. It mainly focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. The company focuses on the mechanistic target of rapamycin (mTOR) pathway which regulates aging, and specifically on selective inhibition of the target of rapamycin complex 1. It is also involved in the development of RTB101 which is a small molecule, potent TORC1 inhibitor. The company's pipeline products include RTB101 and RTB101+ everolimus.

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • 501 Boylston Street
  • Suite 6102
  • Boston, MA 02116
  • United States

+1 (617) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore resTORbio’s full profile, request a free trial.

resTORbio Stock Performance

52 wk Range Market Cap Prev. Close EPS Average Volume Shares
$6.21 - $20.59 $266M $7.60 -$1.35 173K 35.7M

resTORbio Financials Summary

In Thousands,
USD
TTM
31-Mar-2019
FY 2018
31-Dec-2018
FY 2017
31-Dec-2017
FY 2016
31-Dec-2016
Enterprise Value 132,413 270,108
Revenue 0 0 0
EBITDA (38,691) (37,508) (33,773) (1)
Net Income (38,824) (37,614) (33,778)
Total Assets 145,080 109,939 55,193
Public Fundamental Data provided by Morningstar, Inc. disclaimer

resTORbio Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore resTORbio‘s full profile, request access.

Request full access to PitchBook

resTORbio Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is reserved for PitchBook Platform users. To explore resTORbio‘s full profile, request access.

Request full access to PitchBook
To view this company’s complete Cap Table, request access »

resTORbio Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Recyte Therapeutics Angel-Backed Alameda, CA 000.00 0000000000 000.00
00000 000000000000 Formerly VC-backed Brisbane, CA 000 00000 00000000 00000
000000 Corporation Honolulu, HI 00 000.00 000000000 000.00
To view this company’s complete list of competitors, request access »

resTORbio Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore resTORbio‘s full profile, request access.

Request full access to PitchBook

resTORbio Executive Team (4)

Name Title Board
Seat
Contact
Info
Chen Schor Co-Founder, President, Chief Executive Officer & Board of Director
John McCabe Vice President, Finance
Sarb Shergill Ph.D Vice President of Clinical Operations
Joan Mannick MD Co-Founder, Chief Medical Officer & Board of Director

resTORbio Board Members (8)

Name Representing Role Since Contact
Info
Bharatt Chowrira Ph.D PureTech Health Board Member 000 0000
Chen Schor resTORbio Co-Founder, President, Chief Executive Officer & Board of Director 000 0000
Daphne Zohar PureTech Health Board Member 000 0000
David Steinberg PureTech Health Board Member 000 0000
Joan Mannick MD resTORbio Co-Founder, Chief Medical Officer & Board of Director 000 0000
You’re viewing 5 of 8 board members. Get the full list »